| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2014.06.011 |
| P698 | PubMed publication ID | 24952367 |
| P50 | author | Joan L. Warren | Q125599790 |
| P2093 | author name string | Edward L Trimble | |
| Craig C Earle | |||
| Kimberly Murray | |||
| Kathleen M Fairfield | |||
| Heidi R Wierman | |||
| Jason A LaChance | |||
| P2860 | cites work | A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 |
| Assessing comorbidity using claims data: an overview | Q33184142 | ||
| Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 | ||
| Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival | Q36608502 | ||
| Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation | Q37627681 | ||
| Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research | Q39452746 | ||
| Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study | Q40247128 | ||
| The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer | Q42871376 | ||
| Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute | Q46157206 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study | Q57387119 | ||
| Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection | Q82435926 | ||
| Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer | Q95381356 | ||
| P433 | issue | 3 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 473-477 | |
| P577 | publication date | 2014-06-18 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer | |
| P478 | volume | 134 |
| Q37029841 | Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center |
| Q90431035 | Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer |
| Q39352701 | Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women |
| Q88890110 | Ovarian cancer statistics, 2018 |
| Q38555716 | Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. |
| Q38275362 | Treatment of ovarian cancer in the older woman |
| Q36011137 | Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer |
| Q36932625 | Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer |
| Q40105132 | Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population. |
| Q38529445 | Why have ovarian cancer mortality rates declined? Part II. Case-fatality |
Search more.